{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:50:07Z","timestamp":1787788207640,"version":"build-2784847793"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.imlet.2017.10.011","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T16:38:53Z","timestamp":1509035933000},"page":"45-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Targeting interferons as a strategy for systemic sclerosis treatment"],"prefix":"10.1016","volume":"195","author":[{"given":"Marzena","family":"Ciechomska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urszula","family":"Skalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2017.10.011_bib0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/ITT.S82037","article-title":"Current perspectives on the immunopathogenesis of systemic sclerosis","volume":"5","author":"Fuschiotti","year":"2016","journal-title":"Immunotargets Ther."},{"issue":"2","key":"10.1016\/j.imlet.2017.10.011_bib0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/BOR.0b013e32834ff2e8","article-title":"Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers","volume":"24","author":"Barnes","year":"2012","journal-title":"Curr. Opin. Rheumatol."},{"issue":"8","key":"10.1016\/j.imlet.2017.10.011_bib0015","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/art.11073","article-title":"Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population","volume":"48","author":"Mayes","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.imlet.2017.10.011_bib0020","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.imlet.2017.10.011_bib0025","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s13075-015-0819-7","article-title":"Update on mesenchymal stem cell-based therapy in lupus and scleroderma","volume":"17","author":"Cras","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"24","key":"10.1016\/j.imlet.2017.10.011_bib0030","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.imlet.2017.10.011_bib0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11926-015-0555-7","article-title":"Cellular therapies in systemic sclerosis: recent progress","volume":"18","author":"van Rhijn-Brouwer","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/1346-8138.13026","article-title":"Strategy for treatment of fibrosis in systemic sclerosis: present and future","volume":"43","author":"Yanaba","year":"2016","journal-title":"J. Dermatol."},{"issue":"6","key":"10.1016\/j.imlet.2017.10.011_bib0045","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/exd.12673","article-title":"Current frontiers in systemic sclerosis pathogenesis","volume":"24","author":"Ciechomska","year":"2015","journal-title":"Exp. Dermatol."},{"issue":"5","key":"10.1016\/j.imlet.2017.10.011_bib0050","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.autrev.2016.01.007","article-title":"Systemic sclerosis: an update in 2016","volume":"15","author":"Desbois","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.imlet.2017.10.011_bib0055","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s13075-015-0848-2","article-title":"Inhibition of angiogenesis by platelets in systemic sclerosis patients","volume":"17","author":"Hirigoyen","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.imlet.2017.10.011_bib0060","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13075-016-0937-x","article-title":"The crowded crossroad to angiogenesis in systemic sclerosis: where is the key to the problem?","volume":"18","author":"Manetti","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.imlet.2017.10.011_bib0065","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3389\/fimmu.2013.00266","article-title":"The role of type 1 interferon in systemic sclerosis","volume":"4","author":"Wu","year":"2013","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.imlet.2017.10.011_bib0070","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jbspin.2009.03.012","article-title":"Interferons and autoimmune disorders","volume":"76","author":"Meyer","year":"2009","journal-title":"J. Bone Spine"},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2015.07.001","article-title":"Interferon-lambda: immune functions at barrier surfaces and beyond","volume":"43","author":"Lazear","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.imlet.2017.10.011_bib0080","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3389\/fimmu.2016.00628","article-title":"Type III interferons in hepatitis C virus infection","volume":"7","author":"Boisvert","year":"2016","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2008.11.002","article-title":"Interferons: signaling, antiviral and viral evasion","volume":"122","author":"Bonjardim","year":"2009","journal-title":"Immunol. Lett."},{"issue":"6","key":"10.1016\/j.imlet.2017.10.011_bib0090","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1089\/10799900260100132","article-title":"Type I interferon production by plasmacytoid dendritic cells and monocytes is triggered by viruses, but the level of production is controlled by distinct cytokines","volume":"22","author":"Gary-Gouy","year":"2002","journal-title":"J. Interferon Cytokine Res."},{"issue":"3","key":"10.1016\/j.imlet.2017.10.011_bib0095","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0092-8674(94)90154-6","article-title":"The human interferon alpha\/beta receptor: characterization and molecular cloning","volume":"77","author":"Novick","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.imlet.2017.10.011_bib0100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","article-title":"Interferons, interferon-like cytokines, and their receptors","volume":"202","author":"Pestka","year":"2004","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.imlet.2017.10.011_bib0105","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.immunol.26.021607.090400","article-title":"The IRF family transcription factors in immunity and oncogenesis","volume":"26","author":"Tamura","year":"2008","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(99)00262-0","article-title":"Interferon regulatory factors: the next generation","volume":"237","author":"Mamane","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.imlet.2017.10.011_bib0115","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1146\/annurev.immunol.19.1.623","article-title":"IRF family of transcription factors as regulators of host defense","volume":"19","author":"Taniguchi","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.imlet.2017.10.011_bib0120","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1146\/annurev.iy.11.040193.003035","article-title":"The molecular cell biology of interferon-gamma and its receptor","volume":"11","author":"Farrar","year":"1993","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.imlet.2017.10.011_bib0125","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fimmu.2017.00014","article-title":"Protozoan parasites and type I IFNs","volume":"8","author":"Silva-Barrios","year":"2017","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.imlet.2017.10.011_bib0130","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cytogfr.2009.02.004","article-title":"Interferon-gamma: a historical perspective","volume":"20","author":"Billiau","year":"2009","journal-title":"Cytokine Growth Factor Rev."},{"issue":"4","key":"10.1016\/j.imlet.2017.10.011_bib0135","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.coi.2008.05.009","article-title":"Intracellular DNA sensors in immunity","volume":"20","author":"Takeshita","year":"2008","journal-title":"Curr. Opin. Immunol."},{"issue":"7098","key":"10.1016\/j.imlet.2017.10.011_bib0140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nature04946","article-title":"Intracellular pattern recognition receptors in the host response","volume":"442","author":"Meylan","year":"2006","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.imlet.2017.10.011_bib0145","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/08916930902831829","article-title":"Endogenous type I interferon inducers in autoimmune diseases","volume":"42","author":"Finke","year":"2009","journal-title":"Autoimmunity"},{"issue":"10","key":"10.1016\/j.imlet.2017.10.011_bib0150","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.4049\/jimmunol.1000491","article-title":"Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1","volume":"185","author":"Wang","year":"2010","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0155","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/imm.12227","article-title":"Role of miR-155 in the regulation of lymphocyte immune function and disease","volume":"142","author":"Seddiki","year":"2014","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.imlet.2017.10.011_bib0160","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/art.24436","article-title":"MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins","volume":"60","author":"Tang","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.imlet.2017.10.011_bib0165","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1182\/blood-2008-04-152488","article-title":"Suppression of LPS-induced Interferon-gamma and nitric oxide in splenic lymphocytes by select estrogen-regulated microRNAs: a novel mechanism of immune modulation","volume":"112","author":"Dai","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.imlet.2017.10.011_bib0170","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/BOR.0b013e32835c7e32","article-title":"The interferon signature in autoimmune diseases","volume":"25","author":"Ronnblom","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.imlet.2017.10.011_bib0175","unstructured":"http:\/\/interferome.org\/interferome\/home.jspx."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0180","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/jir.2010.0126","article-title":"Systems biology of interferon responses","volume":"31","author":"Hertzog","year":"2011","journal-title":"J. Interferon Cytokine Res."},{"issue":"6","key":"10.1016\/j.imlet.2017.10.011_bib0185","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.4049\/jimmunol.1102038","article-title":"Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells","volume":"189","author":"Yin","year":"2012","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0190","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13075-017-1344-7","article-title":"IFN-lambda1 with Th17 axis cytokines and IFN-alpha define different subsets in systemic lupus erythematosus (SLE)","volume":"19","author":"Oke","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"10","key":"10.1016\/j.imlet.2017.10.011_bib0195","first-page":"1662","article-title":"Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy","volume":"56","author":"Psarras","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.imlet.2017.10.011_bib0200","first-page":"576","article-title":"Interferon production of vitro by leucocytes from patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"45","author":"Neighbour","year":"1981","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.imlet.2017.10.011_bib0205","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.immuni.2006.08.010","article-title":"Type I interferon in systemic lupus erythematosus and other autoimmune diseases","volume":"25","author":"Banchereau","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.imlet.2017.10.011_bib0210","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.0105-2896.2005.00252.x","article-title":"Interferons as pathogenic effectors in autoimmunity","volume":"204","author":"Baccala","year":"2005","journal-title":"Immunol. Rev."},{"issue":"9","key":"10.1016\/j.imlet.2017.10.011_bib0215","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1191\/096120300674499064","article-title":"Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies","volume":"9","author":"Bengtsson","year":"2000","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.imlet.2017.10.011_bib0220","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/ki.2010.71","article-title":"Interferon-alpha and \u2013beta in kidney inflammation","volume":"77","author":"Anders","year":"2010","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.imlet.2017.10.011_bib0225","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1365-2133.2011.10479.x","article-title":"Interferon-alpha stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus","volume":"165","author":"Zahn","year":"2011","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0230","doi-asserted-by":"crossref","first-page":"e000170","DOI":"10.1136\/lupus-2016-000170","article-title":"Interferon (IFN)-lambda is a potential mediator in lupus nephritis","volume":"3","author":"Zickert","year":"2016","journal-title":"Lupus Sci. Med."},{"issue":"7","key":"10.1016\/j.imlet.2017.10.011_bib0235","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E","article-title":"Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy","volume":"43","author":"Ioannou","year":"2000","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"10.1016\/j.imlet.2017.10.011_bib0240","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1182\/blood-2007-05-089086","article-title":"Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis","volume":"110","author":"Denny","year":"2007","journal-title":"Blood"},{"issue":"40","key":"10.1016\/j.imlet.2017.10.011_bib0245","doi-asserted-by":"crossref","first-page":"16276","DOI":"10.1073\/pnas.1209372109","article-title":"Dual signaling by innate and adaptive immune receptors is required for TLR7-induced B-cell-mediated autoimmunity","volume":"109","author":"Walsh","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.imlet.2017.10.011_bib0250","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1074-7613(01)00126-1","article-title":"Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo","volume":"14","author":"Le Bon","year":"2001","journal-title":"Immunity"},{"issue":"16","key":"10.1016\/j.imlet.2017.10.011_bib0255","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1073\/pnas.0701266104","article-title":"Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus","volume":"104","author":"Graham","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.imlet.2017.10.011_bib0260","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/art.30193","article-title":"Association of a functional IRF7 variant with systemic lupus erythematosus","volume":"63","author":"Fu","year":"2011","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.imlet.2017.10.011_bib0265","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/CIRCGENETICS.113.000044","article-title":"Coronary heart disease in systemic lupus erythematosus is associated with interferon regulatory factor-8 gene variants","volume":"6","author":"Leonard","year":"2013","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.imlet.2017.10.011_bib0270","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fimmu.2013.00142","article-title":"The interferon-signature of Sjogren\u2019s syndrome: how unique biomarkers can identify underlying inflammatory and immunopathological mechanisms of specific diseases","volume":"4","author":"Nguyen","year":"2013","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.imlet.2017.10.011_bib0275","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/art.21893","article-title":"Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren\u2019s syndrome autoantigen-associated RNA","volume":"54","author":"Lovgren","year":"2006","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.imlet.2017.10.011_bib0280","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/art.20998","article-title":"Activation of the type I interferon system in primary Sjogren\u2019s syndrome: a possible etiopathogenic mechanism","volume":"52","author":"Bave","year":"2005","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"10.1016\/j.imlet.2017.10.011_bib0285","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1073\/pnas.0510837103","article-title":"Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren\u2019s syndrome","volume":"103","author":"Gottenberg","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.imlet.2017.10.011_bib0290","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/art.21006","article-title":"Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren\u2019s syndrome patients from healthy control subjects","volume":"52","author":"Hjelmervik","year":"2005","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.imlet.2017.10.011_bib0295","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaut.2009.05.001","article-title":"Gene expression and chromosomal location for susceptibility to Sjogren\u2019s syndrome","volume":"33","author":"Perez","year":"2009","journal-title":"J. Autoimmun."},{"issue":"4","key":"10.1016\/j.imlet.2017.10.011_bib0300","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/gene.2009.20","article-title":"Peripheral blood gene expression profiling in Sjogren\u2019s syndrome","volume":"10","author":"Emamian","year":"2009","journal-title":"Genes Immun."},{"issue":"5","key":"10.1016\/j.imlet.2017.10.011_bib0305","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.tripleo.2009.01.039","article-title":"Expression of interferon regulatory factor 1, 3, and 7 in primary Sjogren syndrome","volume":"107","author":"Zheng","year":"2009","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"issue":"5","key":"10.1016\/j.imlet.2017.10.011_bib0310","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","article-title":"Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren\u2019s syndrome and association with disease activity and BAFF gene expression","volume":"72","author":"Brkic","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.imlet.2017.10.011_bib0315","first-page":"BR191","article-title":"cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies","volume":"10","author":"Zhou","year":"2004","journal-title":"Med. Sci. Monit."},{"issue":"9","key":"10.1016\/j.imlet.2017.10.011_bib0320","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1002\/art.27529","article-title":"Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells","volume":"62","author":"Shrestha","year":"2010","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"10.1016\/j.imlet.2017.10.011_bib0325","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann. Rheumatol Dis."},{"issue":"6","key":"10.1016\/j.imlet.2017.10.011_bib0330","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/art.24555","article-title":"Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy","volume":"60","author":"Niewold","year":"2009","journal-title":"Arthritis Rheumatol."},{"issue":"1\u20132","key":"10.1016\/j.imlet.2017.10.011_bib0335","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol. Med."},{"issue":"12","key":"10.1016\/j.imlet.2017.10.011_bib0340","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1002\/art.27702","article-title":"Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients","volume":"62","author":"Thurlings","year":"2010","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"10.1016\/j.imlet.2017.10.011_bib0345","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/annrheumdis-2012-202753","article-title":"The type I IFN signature as a biomarker of preclinical rheumatoid arthritis","volume":"72","author":"Lubbers","year":"2013","journal-title":"Ann. Rheumatol. Dis."},{"issue":"3","key":"10.1016\/j.imlet.2017.10.011_bib0350","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/art.27294","article-title":"Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis","volume":"62","author":"van Baarsen","year":"2010","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0355","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/keu299","article-title":"Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy","volume":"54","author":"Wright","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.imlet.2017.10.011_bib0360","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","volume":"75","author":"Brkic","year":"2016","journal-title":"Ann. Rheumatol. Dis."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0365","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13075-017-1237-9","article-title":"Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes","volume":"19","author":"Farina","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.imlet.2017.10.011_bib0370","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/art.39602","article-title":"Histone demethylation and toll-like receptor 8-dependent cross-talk in monocytes promotes transdifferentiation of fibroblasts in systemic sclerosis via fra-2","volume":"68","author":"Ciechomska","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.imlet.2017.10.011_bib0375","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/art.22382","article-title":"A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists","volume":"56","author":"York","year":"2007","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.imlet.2017.10.011_bib0380","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/art.27220","article-title":"A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis","volume":"62","author":"Farina","year":"2010","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.imlet.2017.10.011_bib0385","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/ard.2009.121400","article-title":"Type I interferon system activation and association with disease manifestations in systemic sclerosis","volume":"69","author":"Eloranta","year":"2010","journal-title":"Ann. Rheumatol. Dis."},{"issue":"7","key":"10.1016\/j.imlet.2017.10.011_bib0390","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.23486","article-title":"Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis","volume":"58","author":"Kim","year":"2008","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0395","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1046\/j.1365-2249.1999.00842.x","article-title":"Increased interferon-gamma (IFN-gamma) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud\u2019s phenomenon","volume":"116","author":"Molteni","year":"1999","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.imlet.2017.10.011_bib0400","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1365-2249.2001.01603.x","article-title":"Circulating gamma\/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization","volume":"125","author":"Giacomelli","year":"2001","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.imlet.2017.10.011_bib0405","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/art.27224","article-title":"Systemic sclerosis and lupus: points in an interferon-mediated continuum","volume":"62","author":"Assassi","year":"2010","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"10.1016\/j.imlet.2017.10.011_bib0410","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/jcp.24337","article-title":"Interferon-gamma promotes vascular remodeling in human microvascular endothelial cells by upregulating endothelin (ET)-1 and transforming growth factor (TGF) beta2","volume":"228","author":"Chrobak","year":"2013","journal-title":"J. Cell. Physiol."},{"issue":"6766","key":"10.1016\/j.imlet.2017.10.011_bib0415","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/35003221","article-title":"Interferon-gamma elicits arteriosclerosis in the absence of leukocytes","volume":"403","author":"Tellides","year":"2000","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.imlet.2017.10.011_bib0420","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.addr.2007.11.005","article-title":"TLR3: interferon induction by double-stranded RNA including poly(I:C)","volume":"60","author":"Matsumoto","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0425","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1186\/ar3221","article-title":"Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts","volume":"13","author":"Agarwal","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.imlet.2017.10.011_bib0430","first-page":"e436","article-title":"The th1 chemokine IP-10 in systemic sclerosis","volume":"165","author":"Corrado","year":"2014","journal-title":"Clin. Ther."},{"issue":"11","key":"10.1016\/j.imlet.2017.10.011_bib0435","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1038\/jid.2010.200","article-title":"Poly(I:C) drives type I IFN- and TGFbeta-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis","volume":"130","author":"Farina","year":"2010","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0440","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1371\/journal.pone.0001452","article-title":"Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?","volume":"3","author":"Fleming","year":"2008","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.imlet.2017.10.011_bib0445","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/bmt.2009.35","article-title":"Improvements in digital vasculature observed using micro magnetic resonance angiography after high-dose immunosuppression for severe systemic sclerosis","volume":"44","author":"Wang","year":"2009","journal-title":"Bone Marrow Transplant."},{"issue":"49","key":"10.1016\/j.imlet.2017.10.011_bib0450","doi-asserted-by":"crossref","first-page":"15136","DOI":"10.1073\/pnas.1520997112","article-title":"Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis","volume":"112","author":"Saigusa","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.imlet.2017.10.011_bib0455","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.38288","article-title":"Association of Interferon- and transforming growth factor beta-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis","volume":"66","author":"Christmann","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"10.1016\/j.imlet.2017.10.011_bib0460","first-page":"625","article-title":"Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis","volume":"22","author":"Solans","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"issue":"4","key":"10.1016\/j.imlet.2017.10.011_bib0465","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/jid.2013.423","article-title":"Epstein-Barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in scleroderma","volume":"134","author":"Farina","year":"2014","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.imlet.2017.10.011_bib0470","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nri3133","article-title":"Immunomodulatory functions of type I interferons","volume":"12","author":"Gonzalez-Navajas","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.imlet.2017.10.011_bib0475","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.autrev.2010.09.015","article-title":"Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy","volume":"10","author":"Wei","year":"2011","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0480","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.21526","article-title":"Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes","volume":"54","author":"Matsushita","year":"2006","journal-title":"Arthritis Rheumatol."},{"issue":"1\u20132","key":"10.1016\/j.imlet.2017.10.011_bib0485","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cellimm.2008.09.003","article-title":"Enhanced induction of LPS-induced fibroblast MCP-1 by interferon-gamma: involvement of JNK and MAPK phosphatase-1","volume":"255","author":"Yamana","year":"2009","journal-title":"Cell. Immunol."},{"issue":"3","key":"10.1016\/j.imlet.2017.10.011_bib0490","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.4049\/jimmunol.179.3.1942","article-title":"IFN-gamma-mediated survival enables human neutrophils to produce MCP-1\/CCL2 in response to activation by TLR ligands","volume":"179","author":"Yoshimura","year":"2007","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.imlet.2017.10.011_bib0495","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/1529-0131(200111)44:11<2665::AID-ART446>3.0.CO;2-S","article-title":"Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis","volume":"44","author":"Distler","year":"2001","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.imlet.2017.10.011_bib0500","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/1529-0131(200106)44:6<1382::AID-ART231>3.0.CO;2-T","article-title":"Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression","volume":"44","author":"Galindo","year":"2001","journal-title":"Arthritis Rheumatol."},{"issue":"1\u20132","key":"10.1016\/j.imlet.2017.10.011_bib0505","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0014-5793(03)00863-9","article-title":"Viral dsRNA activates mucin transcription in airway epithelial cells","volume":"553","author":"Londhe","year":"2003","journal-title":"FEBS Lett."},{"key":"10.1016\/j.imlet.2017.10.011_bib0510","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s13104-015-1510-4","article-title":"Molecular network of important genes for systemic sclerosis-related progressive lung fibrosis","volume":"8","author":"Jiao","year":"2015","journal-title":"BMC Res. Notes"},{"issue":"Suppl","key":"10.1016\/j.imlet.2017.10.011_bib0515","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1038\/ki.2010.418","article-title":"Mechanistic connection between inflammation and fibrosis","volume":"119","author":"Lee","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.imlet.2017.10.011_bib0520","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1017\/erm.2013.10","article-title":"Role of toll-like receptors in systemic sclerosis","volume":"15","author":"Ciechomska","year":"2013","journal-title":"Expert Rev. Mol. Med."},{"issue":"5","key":"10.1016\/j.imlet.2017.10.011_bib0525","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1042\/CS20130367","article-title":"Innate immunity in systemic sclerosis pathogenesis","volume":"126","author":"O\u2019Reilly","year":"2014","journal-title":"Clin. Sci. (Lond.)"},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0530","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","article-title":"The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index","volume":"76","author":"Valentini","year":"2017","journal-title":"Ann. Rheumatol. Dis."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0535","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2217\/bmm.09.79","article-title":"Biomarkers in systemic sclerosis","volume":"4","author":"Castro","year":"2010","journal-title":"Biomark. Med."},{"issue":"3","key":"10.1016\/j.imlet.2017.10.011_bib0540","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.4049\/jimmunol.1303230","article-title":"Increased IFN-alpha-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-alpha production","volume":"193","author":"Xia","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.imlet.2017.10.011_bib0545","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-stimulated genes: a complex web of host defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.imlet.2017.10.011_bib0550","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1046\/j.1365-2249.2002.02017.x","article-title":"Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis","volume":"130","author":"Fujii","year":"2002","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0555","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13075-016-1213-9","article-title":"TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients","volume":"19","author":"Aravena","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.imlet.2017.10.011_bib0560","first-page":"105","article-title":"Vascular involvement in systemic sclerosis (scleroderma)","volume":"4","author":"Pattanaik","year":"2011","journal-title":"J. Inflamm. Res."},{"issue":"11","key":"10.1016\/j.imlet.2017.10.011_bib0565","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3899\/jrheum.080418","article-title":"Upregulation of myxovirus-resistance protein A: a possible marker of type I interferon induction in systemic sclerosis","volume":"35","author":"Airo","year":"2008","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.imlet.2017.10.011_bib0570","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/gene.2008.98","article-title":"Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers","volume":"10","author":"Bos","year":"2009","journal-title":"Genes Immun."},{"issue":"4","key":"10.1016\/j.imlet.2017.10.011_bib0575","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2353\/ajpath.2010.090593","article-title":"Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy","volume":"176","author":"Asano","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0580","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pharmthera.2008.10.002","article-title":"Therapeutic targets in pulmonary arterial hypertension","volume":"121","author":"Rhodes","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.imlet.2017.10.011_bib0585","doi-asserted-by":"crossref","first-page":"147616","DOI":"10.1155\/2015\/147616","article-title":"Endothelin receptors expressed by immune cells are involved in modulation of inflammation and in fibrosis: relevance to the pathogenesis of systemic sclerosis","volume":"2015","author":"Elisa","year":"2015","journal-title":"J. Immunol. Res."},{"issue":"8","key":"10.1016\/j.imlet.2017.10.011_bib0590","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1002\/art.34424","article-title":"Wnt\/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells","volume":"64","author":"Wei","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.imlet.2017.10.011_bib0595","first-page":"647","article-title":"Lymphocyte-endothelium interaction in systemic sclerosis and Raynaud\u2019s phenomenon","volume":"19","author":"Della Bella","year":"2001","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.imlet.2017.10.011_bib0600","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2016-210645","article-title":"Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis","volume":"76","author":"Terao","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.imlet.2017.10.011_bib0605","doi-asserted-by":"crossref","first-page":"e1002091","DOI":"10.1371\/journal.pgen.1002091","article-title":"Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis","volume":"7","author":"Allanore","year":"2011","journal-title":"PLoS Genet."},{"key":"10.1016\/j.imlet.2017.10.011_bib0610","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13075-015-0572-y","article-title":"Identification of NF-kappaB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis","volume":"17","author":"Arismendi","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"10.1016\/j.imlet.2017.10.011_bib0615","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.4049\/jimmunol.179.11.7614","article-title":"PRDM1\/BLIMP-1 modulates IFN-gamma-dependent control of the MHC class I antigen-processing and peptide-loading pathway","volume":"179","author":"Doody","year":"2007","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.imlet.2017.10.011_bib0620","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/ni.3348","article-title":"Blimp-1 controls plasma cell function through the regulation of immunoglobulin secretion and the unfolded protein response","volume":"17","author":"Tellier","year":"2016","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0625","doi-asserted-by":"crossref","first-page":"e54419","DOI":"10.1371\/journal.pone.0054419","article-title":"The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis","volume":"8","author":"Carmona","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.imlet.2017.10.011_bib0630","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/ng.565","article-title":"Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus","volume":"42","author":"Radstake","year":"2010","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.imlet.2017.10.011_bib0635","doi-asserted-by":"crossref","first-page":"e1002178","DOI":"10.1371\/journal.pgen.1002178","article-title":"Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy","volume":"7","author":"Gorlova","year":"2011","journal-title":"PLoS Genet."},{"issue":"7","key":"10.1016\/j.imlet.2017.10.011_bib0640","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1136\/annrheumdis-2011-200901","article-title":"IRF5 polymorphism predicts prognosis in patients with systemic sclerosis","volume":"71","author":"Sharif","year":"2012","journal-title":"Ann. Rheumatol. Dis."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0645","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/art.24183","article-title":"Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis","volume":"60","author":"Dieude","year":"2009","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.imlet.2017.10.011_bib0650","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/039463201402700420","article-title":"Association of the IRF5 SNP rs2004640 with systemic sclerosis in Han Chinese","volume":"27","author":"Wang","year":"2014","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"4","key":"10.1016\/j.imlet.2017.10.011_bib0655","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/ijd.12839","article-title":"Polymorphisms in STAT4 and IRF5 increase the risk of systemic sclerosis: a meta-analysis","volume":"55","author":"Xu","year":"2016","journal-title":"Int. J. Dermatol."},{"issue":"6","key":"10.1016\/j.imlet.2017.10.011_bib0660","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/art.24600","article-title":"Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population","volume":"60","author":"Ito","year":"2009","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.imlet.2017.10.011_bib0665","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/art.37777","article-title":"PLD4 as a novel susceptibility gene for systemic sclerosis in a Japanese population","volume":"65","author":"Terao","year":"2013","journal-title":"Arthritis Rheumatol."},{"issue":"15","key":"10.1016\/j.imlet.2017.10.011_bib0670","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1074\/jbc.M507788200","article-title":"IRF-8\/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways","volume":"281","author":"Zhao","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.imlet.2017.10.011_bib0675","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/jid.2015.188","article-title":"Suppression of T cell activation and collagen accumulation by an anti-IFNAR1 mAb, anifrolumab, in adult patients with systemic sclerosis","volume":"135","author":"Guo","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.imlet.2017.10.011_bib0680","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/19420862.2015.1007810","article-title":"Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-alpha receptor 1 antibody","volume":"7","author":"Peng","year":"2015","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0685","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar4492","article-title":"Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study","volume":"16","author":"Goldberg","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.imlet.2017.10.011_bib0690","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri3806","article-title":"Regulation of antiviral T cell responses by type I interferons","volume":"15","author":"Crouse","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.imlet.2017.10.011_bib0695","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"10.1016\/j.imlet.2017.10.011_bib0700","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann. Rheumatol. Dis."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0705","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann. Rheumatol. Dis."},{"issue":"1","key":"10.1016\/j.imlet.2017.10.011_bib0710","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.0105-2896.2009.00867.x","article-title":"Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells","volume":"234","author":"Cao","year":"2010","journal-title":"Immunol. Rev."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247817302535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247817302535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T10:17:12Z","timestamp":1621073832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247817302535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":142,"alternative-id":["S0165247817302535"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2017.10.011","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting interferons as a strategy for systemic sclerosis treatment","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2017.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}